China GL Capital claims 5% stake in U.K.'s Oxford BioDynamics

Epigenetic biomarker company Oxford BioDynamics plc (LSE:OBD) partnered with GL Capital Group to address demand for healthcare and personalized medicine in China. The Greater China healthcare-focused firm will act as the U.K.-based biotech's lead mainland

Read the full 352 word article

User Sign In